HCV related severe cryoglobulinemic vasculitis treated with plasma exchange and rituximab: case report and literature review
Mixed cryoglobulinemia is the most prevalent extrahepatic manifestation of chronic HCV infection. It is usually a benign lymphoproliferative disorder which presents as vasculitis affecting different organs. Although life-threatening cryoglobulinemic vasculitis (CryoVas) is rare, it is sometimes the...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2017-06-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/8290 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849313623167467520 |
|---|---|
| author | Snezana Arandjelovic Branka Bonaci-Nikolic Aleksandra Peric-Popadic Vesna Tomic-Spiric Jasna Bolpacic Sanvila Raskovic Sladjana Andrejevic |
| author_facet | Snezana Arandjelovic Branka Bonaci-Nikolic Aleksandra Peric-Popadic Vesna Tomic-Spiric Jasna Bolpacic Sanvila Raskovic Sladjana Andrejevic |
| author_sort | Snezana Arandjelovic |
| collection | DOAJ |
| description |
Mixed cryoglobulinemia is the most prevalent extrahepatic manifestation of chronic HCV infection. It is usually a benign lymphoproliferative disorder which presents as vasculitis affecting different organs. Although life-threatening cryoglobulinemic vasculitis (CryoVas) is rare, it is sometimes the first and possibly lethal complication. Its treatment depends on the severity of vasculitis and can be challenging. High dose of corticosteroids, immunosuppressive agents and plasma exchange represent the first-line treatment, which should be followed by antiviral therapy. Rituximab is an effective and safe treatment option. However, the data about its use in life-threatening conditions are scarce. We report the case of a patient with severe, relapsing and life-threatening HCV-related CryoVas resistant to standard therapy who had had an initial beneficial response to rituximab added to plasma exchange that was later compromised by the development of sepsis. We also review the literature and discuss manifestations and therapy of life-threatening Cryovas with focus on rituximab use.
|
| format | Article |
| id | doaj-art-1c40b4697d0f48d7b4eb3c9d44fe840e |
| institution | Kabale University |
| issn | 1972-2680 |
| language | English |
| publishDate | 2017-06-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-1c40b4697d0f48d7b4eb3c9d44fe840e2025-08-20T03:52:42ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802017-06-01110510.3855/jidc.8290HCV related severe cryoglobulinemic vasculitis treated with plasma exchange and rituximab: case report and literature reviewSnezana Arandjelovic0Branka Bonaci-Nikolic1Aleksandra Peric-Popadic2Vesna Tomic-Spiric3Jasna Bolpacic4Sanvila Raskovic5Sladjana Andrejevic6Clinical Centre of Serbia, Belgrade, SerbiaClinical Centre of Serbia, Belgrade, SerbiaClinical Centre of Serbia, Belgrade, SerbiaClinical Centre of Serbia, Belgrade, SerbiaClinical Centre of Serbia, Belgrade, SerbiaClinical Centre of Serbia, Belgrade, SerbiaClinical Centre of Serbia, Belgrade, Serbia Mixed cryoglobulinemia is the most prevalent extrahepatic manifestation of chronic HCV infection. It is usually a benign lymphoproliferative disorder which presents as vasculitis affecting different organs. Although life-threatening cryoglobulinemic vasculitis (CryoVas) is rare, it is sometimes the first and possibly lethal complication. Its treatment depends on the severity of vasculitis and can be challenging. High dose of corticosteroids, immunosuppressive agents and plasma exchange represent the first-line treatment, which should be followed by antiviral therapy. Rituximab is an effective and safe treatment option. However, the data about its use in life-threatening conditions are scarce. We report the case of a patient with severe, relapsing and life-threatening HCV-related CryoVas resistant to standard therapy who had had an initial beneficial response to rituximab added to plasma exchange that was later compromised by the development of sepsis. We also review the literature and discuss manifestations and therapy of life-threatening Cryovas with focus on rituximab use. https://jidc.org/index.php/journal/article/view/8290hepatitis C virushepatitis C virus (HCV)HCVcryoglobulinemic vasculitislife-threatening cryoglobulinemiarituximab |
| spellingShingle | Snezana Arandjelovic Branka Bonaci-Nikolic Aleksandra Peric-Popadic Vesna Tomic-Spiric Jasna Bolpacic Sanvila Raskovic Sladjana Andrejevic HCV related severe cryoglobulinemic vasculitis treated with plasma exchange and rituximab: case report and literature review Journal of Infection in Developing Countries hepatitis C virus hepatitis C virus (HCV) HCV cryoglobulinemic vasculitis life-threatening cryoglobulinemia rituximab |
| title | HCV related severe cryoglobulinemic vasculitis treated with plasma exchange and rituximab: case report and literature review |
| title_full | HCV related severe cryoglobulinemic vasculitis treated with plasma exchange and rituximab: case report and literature review |
| title_fullStr | HCV related severe cryoglobulinemic vasculitis treated with plasma exchange and rituximab: case report and literature review |
| title_full_unstemmed | HCV related severe cryoglobulinemic vasculitis treated with plasma exchange and rituximab: case report and literature review |
| title_short | HCV related severe cryoglobulinemic vasculitis treated with plasma exchange and rituximab: case report and literature review |
| title_sort | hcv related severe cryoglobulinemic vasculitis treated with plasma exchange and rituximab case report and literature review |
| topic | hepatitis C virus hepatitis C virus (HCV) HCV cryoglobulinemic vasculitis life-threatening cryoglobulinemia rituximab |
| url | https://jidc.org/index.php/journal/article/view/8290 |
| work_keys_str_mv | AT snezanaarandjelovic hcvrelatedseverecryoglobulinemicvasculitistreatedwithplasmaexchangeandrituximabcasereportandliteraturereview AT brankabonacinikolic hcvrelatedseverecryoglobulinemicvasculitistreatedwithplasmaexchangeandrituximabcasereportandliteraturereview AT aleksandrapericpopadic hcvrelatedseverecryoglobulinemicvasculitistreatedwithplasmaexchangeandrituximabcasereportandliteraturereview AT vesnatomicspiric hcvrelatedseverecryoglobulinemicvasculitistreatedwithplasmaexchangeandrituximabcasereportandliteraturereview AT jasnabolpacic hcvrelatedseverecryoglobulinemicvasculitistreatedwithplasmaexchangeandrituximabcasereportandliteraturereview AT sanvilaraskovic hcvrelatedseverecryoglobulinemicvasculitistreatedwithplasmaexchangeandrituximabcasereportandliteraturereview AT sladjanaandrejevic hcvrelatedseverecryoglobulinemicvasculitistreatedwithplasmaexchangeandrituximabcasereportandliteraturereview |